Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review

References

• Alcohol and Drug Foundation. 2019. Drug wheel. Accessed June 28, 2021. https://adf.org.au/insights/drug-wheel.
   Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders. 5th. Accessed June 28, 2021. 10.1176/appi.books.9780890425596.
   Google Scholar
• Argento, E., R. Capler, G. Thomas, P. Lucas, and K. W. Tupper. 2019. A qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug and Alcohol Review 38 (7):781–89. doi:10.1111/dar.12985.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. R. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Brown, T. K., and K. Alper. 2018. Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse 44 (1):24–36. doi:10.1080/00952990.2017.1320802.
   PubMed Web of Science ®Google Scholar
• Chesney, E., G. M. Goodwin, and S. Fazel. 2014. Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry 13 (2):153–60. doi:10.1002/wps.20128.
   PubMed Web of Science ®Google Scholar
• Clarivate. 2021. Web of Science. Accessed June 28, 2021. https://clarivate.com/webofsciencegroup/solutions/web-of-science.
   Google Scholar
• Cloutier-Gill, L., E. Wood, T. Millar, C. Ferris, and M. Eugenia Socias. 2016. Remission of severe opioid use disorder with ibogaine: A case report. Journal of Psychoactive Drugs 48 (3):214–17. doi:10.1080/02791072.2016.1180467.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., E. Renn, A. M. Windham-Herman, M. Polanco, and J. P. Barsuglia. 2018. A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification. Journal of Psychoactive Drugs 50 (4):287–97. doi:10.1080/02791072.2018.1487607.
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., F. Charlson, A. Ferrari, D. Santomauro, H. Erskine, A. Mantilla-Herrara, H. Whiteford, J. Leung, M. Naghavi, M. Griswold, et al. 2018. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: A systematic analysis for the global burden of disease study 2016. The Lancet Psychiatry 5 (12):987–1012. doi:10.1016/S2215-0366(18)30337-7.
   PubMed Web of Science ®Google Scholar
• De Veen, B. T. H., A. F. A. Schellekens, M. M. M. Verheij, and J. R. Homberg. 2017. Psilocybin for treating substance use disorders? Expert Review of Neurotherapeutics 17 (2):203–12. doi:10.1080/14737175.2016.1220834.
   PubMed Web of Science ®Google Scholar
• di Leo, F. 1975. The use of psychedelics in psychotherapy. Journal of Altered States of Consciousness 2 (4):325–37.
   Web of Science ®Google Scholar
• DiVito, A. J., and R. F. Leger. 2020. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: A review. Molecular Biology Reports 47 (12):9791–99. doi:10.1007/s11033-020-06009-x.
   PubMed Web of Science ®Google Scholar
• dos Santos, R. G. 2013. Safety and side effects of ayahuasca in humans-an overview focusing on developmental toxicology. Journal of Psychoactive Drugs 45 (1):68–78. doi:10.1080/02791072.2013.763564.
   PubMed Web of Science ®Google Scholar
• dos Santos, R.G., J. C. Bouso, M. Á. Alcázar-Córcoles, and J. E. C. Hallak. 2018. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Review of Clinical Pharmacology 11 (9):889–902. doi:10.1080/17512433.2018.1511424.
   PubMed Web of Science ®Google Scholar
• Dos Santos, R. G., F. L. Osorio, J. A. S. Crippa, J. Riba, A. Zuardi, and J. E. C. Hallak. 2016. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): A systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology 6 (3):193–213. doi:10.1177/2045125316638008.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu, A., R. R. Griffiths, and M. W. Johnson. 2014. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews 7 (3):157–64. doi:10.2174/1874473708666150107121331.
   PubMedGoogle Scholar
• Garcia-Romeu, A., B. Kersgaard, and P. H. Addy. 2016. Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology 24 (4):229–68. doi:10.1037/pha0000084.
   PubMed Web of Science ®Google Scholar
• Glue, P., G. Cape, D. Tunnicliff, M. Lockhart, F. Lam, N. Hung, C. T. Hung, S. Harland, J. Devane, R. S. Crockett, et al. 2016. Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development 5 (6):460–68. doi:10.1002/cpdd.254.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, M. W. Johnson, U. D. McCann, and R. Jesse. 2008. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology 22 (6):621–32. doi:10.1177/0269881108094300.
   PubMed Web of Science ®Google Scholar
• Joanna Briggs Institute. 2014. Methodology for JBI mixed methods systematic reviews. Accessed June 28, 2021. https://nursing.lsuhsc.edu/JBI/docs/ReviewersManuals/Mixed-Methods.pdf.
   Google Scholar
• Johnson, M. W., A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths. 2014. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology 28 (11):983–92. doi:10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2017. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43 (1):55–60. doi:10.3109/00952990.2016.1170135.
   PubMed Web of Science ®Google Scholar
• Kuypers, K. P. C. 2019. Psychedelic medicine: The biology underlying the persisting psychedelic effects. Medical Hypotheses 125:21–24. doi:10.1016/j.mehy.2019.02.029.
   PubMed Web of Science ®Google Scholar
• Lappan, S. N., A. W. Brown, and P. S. Hendricks. 2020. Dropout rates of in-person psychosocial substance use disorder treatments: A systematic review and meta-analysis. Addiction 115 (2):201–17. doi:10.1111/add.14793.
   PubMed Web of Science ®Google Scholar
• Lizarondo, L., C. Stern, J. Carrier, C. Godfrey, K. Rieger, S. Salmond, J. Apostolo, P. Kirkpatrick, and H. Loveday. 2020. Mixed methods systematic reviews (Chapter 8). In JBI manual for evidence synthesis, ed. E. Aromataris and Z. Munn, Accessed April 15, 2022. https://synthesismanual.jbi.global.
   Google Scholar
• Lowe, H., N. Toyang, B. Steele, H. Valentine, J. Grant, A. Ali, W. Ngwa, and L. Gordon. 2021. The therapeutic potential of psilocybin. Molecules 26 (10):2948–81. doi:10.3390/molecules26102948.
   PubMed Web of Science ®Google Scholar
• Mačiulaitis, R., V. Kontrimavičiūtė, F. Bressolle, and V. Briedis. 2008. Ibogaine, an anti-addictive drug: Pharmacology and time to go further in development. A narrative review. Human & Experimental Toxicology (0960-3271) 27 (3):181. doi:10.1177/0960327107087802.
   PubMed Web of Science ®Google Scholar
• Malcolm, B. J., M. Polanco, and J. Barsuglia. 2018. Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. Journal of Psychoactive Drugs 50 (3):256–65. doi:10.1080/02791072.2018.1447175.
   PubMed Web of Science ®Google Scholar
• Maremmani, A. G. I., P. P. Pani, L. Rovai, S. Bacciardi, and I. Maremmani. 2017. Toward the identification of a specific psychopathology of substance use disorders. Frontiers in Psychiatry 8 (68):1–11. doi:10.3389/fpsyt.2017.00068.
   PubMedGoogle Scholar
• Mash, D. C., L. Duque, B. Page, and K. Allen-Ferdinand. 2018. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology 9 (529):1–12. doi:10.3389/fphar.2018.00529.
   PubMedGoogle Scholar
• Mertens, L. J., M. B. Wall, L. Roseman, L. Demetriou, D. J. Nutt, and R. L. Carhart-Harris. 2020. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal of Psychopharmacology 34 (2):167–80. doi:10.1177/0269881119895520.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). 2012. Drug use disorders in adults – Quality standard [QS23]. London: NICE.
   Google Scholar
• Nielson, E. M., D. G. May, A. A. Forcehimes, and M. P. Bogenschutz. 2018. The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions. Frontiers in Pharmacology 9 (132):1–13. doi:10.3389/fphar.2018.00132.
   PubMedGoogle Scholar
• Nutt, D. J., L. A. King, and D. E. Nichols. 2013. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience 14 (8):577–85. doi:10.1038/nrn3530.
   PubMed Web of Science ®Google Scholar
• Page, M. J., J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, et al. 2021. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. British Medical Journal 372 (71):1–9. doi:10.1136/bmj.n71.
   Google Scholar
• Pasareanu, A. R., A. Ospal, J. K. Vederhus, Ø. Kristensen, and T. Clausen. 2015. Quality of life improved following in-patient substance use disorder treatment. Health and Quality of Life Outcomes 13 (1):1–8. doi:10.1186/s12955-015-0231-7.
   PubMed Web of Science ®Google Scholar
• Passie, T., J. H. Halpern, D. O. Stichtenoth, H. M. Emrich, and A. Hintzen. 2008. The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics 14 (4):295–314. doi:10.1111/j.1755-5949.2008.00059.x.
   PubMed Web of Science ®Google Scholar
• Pisano, V. D., N. P. Putnam, H. M. Kramer, K. J. Franciotti, J. H. Halper, and S. C. Holden. 2017. The association of psychedelic use and opioid use disorders among illicit users in the United States. Journal of Psychopharmacology 31 (5):606–13. doi:10.1177/0269881117691453.
   PubMed Web of Science ®Google Scholar
• Sellers, E. M., and D. B. Leiderman. 2018. Psychedelic drugs as therapeutics: No illusions about the challenges. Clinical Pharmacology & Therapeutics 103 (4):561–64. doi:10.1002/cpt.776.
   PubMed Web of Science ®Google Scholar
• Sharma, R., and J. Sin. 2021. A mixed methods systematic review of contemporary psychedelic-associated treatments for substance use disorders and substance misuse. Accessed June 28, 2022. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021232944.
   Google Scholar
• Soler, J., M. Elices, A. Franquesa, S. Barker, P. Friedlander, A. Feilding, J. C. Pascual, and J. Riba. 2016. Exploring the therapeutic potential of ayahuasca: Acute intake increases mindfulness-related capacities. Psychopharmacology 233 (5):823–29. doi:10.1007/s00213-015-4162-0.
   PubMed Web of Science ®Google Scholar
• Taylor, W. J. 1971. History and pharmacology of psychedelic drugs. International Journal of Clinical Pharmacology, Therapy & Toxicology 5 (1):51–57.
   Google Scholar
• Thomas, G., P. Lucas, N. R. Capler, K. W. Tupper, and G. Martin. 2013. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Current Drug Abuse Reviews 6 (1):30–42. doi:10.2174/15733998113099990003.
   PubMedGoogle Scholar
• Whelan, P. J., and K. Remski. 2012. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. Journal of Neurosciences in Rural Practice 3 (1):45–50. doi:10.4103/0976-3147.91934.
   PubMedGoogle Scholar
• Winkelman, M. 2014. Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, peyote, ibogaine, and ayahuasca. Current Drug Abuse Review 7 (2):101–16. doi:10.2174/1874473708666150107120011.
   PubMedGoogle Scholar
• World Health Organization. 2019. ICD-10 Version:2019. Accessed June, 28 2021. https://icd.who.int/browse10/2019/en.
   Google Scholar
• Zingg, W., E. Castro-Sanchez, F. V. Secci, R. Edwards, L. N. Drumright, N. Sevdalis, and A. H. Holmes. 2015. Innovative tools for quality assessment: Integrated quality criteria for review of multiple study designs (ICROMS). Public Health (London) 133:19–37. doi:10.1016/j.puhe.2015.10.012.
   PubMed Web of Science ®Google Scholar